Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Follow-Up Questions
¿Quién es el CEO de Bicara Therapeutics Inc?
Dr. Claire Mazumdar es el Chief Executive Officer de Bicara Therapeutics Inc, se unió a la empresa desde 2020.
¿Qué tal es el rendimiento del precio de la acción BCAX?
El precio actual de BCAX es de $14.88, ha increased un 0.98% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Bicara Therapeutics Inc?
Bicara Therapeutics Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Bicara Therapeutics Inc?
La capitalización bursátil actual de Bicara Therapeutics Inc es $812.1M
¿Es Bicara Therapeutics Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 9 analistas han realizado calificaciones de análisis para Bicara Therapeutics Inc, incluyendo 4 fuerte compra, 8 compra, 2 mantener, 0 venta, y 4 fuerte venta